Continuous API Manufacturing Platform for Modern Pharmaceutical Production (Continuous Production of Active Pharmaceutical Ingredients, Tech ID: 19‑020)
Technology Overview: This technology expands on continuous pharmaceutical manufacturing by enabling steady‑state production of APIs with precise control over reaction and separation conditions. The platform improves product consistency, reduces batch variability, and significantly lowers manufacturing footprint and operational costs. It aligns with regulatory initiatives promoting continuous processing for improved drug quality and supply chain resilience.
Industry Pain Point: Batch API manufacturing leads to inefficiency, long cycle times, and variable quality.
NJIT Solution: This technology enables robust, continuous API production, improving quality, efficiency, and scalability.
Key Features & Advantages
- Continuous, steady‑state operation
- Improved quality control and consistency
- Reduced capital and operating costs
- Regulatory‑aligned manufacturing approach
Development Stage: TRL 6–7 – Pilot‑scale validation completed.
Target Markets
- Pharmaceutical manufacturers
- Generics and specialty APIs
- CDMOs
Market Opportunity
- Global API market (2026): ~$230B
- CAGR: ~6–7%
- Projected market size (2035): ~$380–400B
Commercial & IP Details
Inventor: Kamalesh Sirkar